Longduoduo Co. Ltd. provides preventive healthcare solutions and services. The company is headquartered in Hohhot, Neimenggu and currently employs 52 full-time employees. The company went IPO on 2022-08-17. The firm provides solution for chronic disease problems through non-drug treatments and prevents cardiovascular and cerebrovascular diseases in advance. The firm offers health consultation and advice to customers and sells treatment services to customers, provided by Longduoduo to customers in local cooperative medical institutions. The firm's treatment projects mainly include ozone autologous blood transfusion (immunotherapy), Xingnao Tongluo therapy, double blood purification, platelet-rich plasma (PRP) injection therapy and others. The firm's products and services are mainly used for the prevention of myocardial infarction, cerebral infarction, hemiplegia, cardiovascular and cerebrovascular diseases. The firm mainly conduct its businesses in domestic market.
LDDD stock price ended at $0.59 on 月曜日, after dropping 36.56%
On the latest trading day Nov 24, 2025, the stock price of LDDD fell by 36.56%, dropping from $0.59 to $0.59. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.59 and a high of $0.59. On the latest trading day, the trading volume for LDDD decreased by 274 shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 100 shares were traded, with a market value of approximately $17.7M.